Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Cyclic - C3  (3D View)
Global Stoichiometry: Homo 3-mer - A3 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 126038.66 
• Atom Count: 7947 
• Residue Count: 1104 
• Unique protein chains: 1

2XAE

Crystal structure of human kinesin Eg5 in complex with (R)-2-amino-3-((S)-2-methyl-1,1-diphenylbutylthio)propanoic acid

• DOI: 10.2210/pdb2XAE/pdb

• Classification: CELL CYCLE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)


• Deposited: 2010-03-31 Released: 2011-03-30 
• Deposition Author(s): Kaan, H.Y.K., Weiss, J., Menger, D., Ulaganathan, V., Tkocz, K., Laggner, C., Popowycz, F., Joseph, B., Kozielski, F.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.6 Å
• R-Value Free: 0.257 
• R-Value Work: 0.181 

Literature

Structure-Activity Relationship and Multidrug Resistance Study of New S-Trityl-L-Cysteine Derivatives as Inhibitors of Eg5.

Kaan, H.Y.K., Weiss, J., Menger, D., Ulaganathan, V., Tkocz, K., Laggner, C., Popowycz, F., Joseph, B., Kozielski, F.

(2011) J.Med.Chem. 54: 1576

• PubMed: 21344920 
• DOI: 10.1021/jm100991m
• Primary Citation of Related Structures:  
  2X2R


• PubMed Abstract: 
  

The mitotic spindle is a validated target for cancer chemotherapy. Drugs such as taxanes and vinca alkaloids specifically target microtubules and cause the mitotic spindle to collapse. However, toxicity and resistance are problems associated with these drugs. Thus, alternative approaches to inhibiting the mitotic spindle are being pursued. These include targeting Eg5, a human kinesin involved in the formation of the bipolar spindle. We previously identified S-trityl-L-cysteine (STLC) as a potent allosteric inhibitor of Eg5. Here, we report the synthesis of a new series of STLC-like compounds with in vitro inhibition in the low nanomolar range. We also performed a multidrug resistance study in cell lines overexpressing P-glycoprotein and showed that some of these inhibitors may have the potential to overcome susceptibility to this efflux pump. Finally, we performed molecular docking of the compounds and determined the structures of two Eg5-inhibitor complexes to explain the structure-activity relationship of these compounds.

---

Organizational Affiliation: 

The Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow G61 1BD, Scotland, UK.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
KINESIN-LIKE PROTEIN KIF11	A, B, C	368	Homo sapiens	Mutation(s): 0  Gene Names: KIF11 (EG5, KNSL1, TRIP5)
Find proteins for P52732 (Homo sapiens) Go to Gene View: KIF11 Go to UniProtKB:  P52732

Small Molecules

Ligands 5 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
SO4	B, C	SULFATE ION O4 S QAOWNCQODCNURD-UHFFFAOYSA-L
ADP	A, B, C	ADENOSINE-5'-DIPHOSPHATE C10 H15 N5 O10 P2 XTWYTFMLZFPYCI-KQYNXXCUSA-N
CL	A	CHLORIDE ION Cl VEXZGXHMUGYJMC-UHFFFAOYSA-M
MG	A, B, C	MAGNESIUM ION Mg JLVVSXFLKOJNIY-UHFFFAOYSA-N
2XA	A, B, C	(2R)-2-AMINO-3-[(4-CHLOROPHENYL)-DIPHENYL-METHYL]SULFANYL-PROPANOIC ACID C22 H20 Cl N O2 S BSTXYLCINUXYQF-FQEVSTJZSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
2XA	IC50: 53.3 nM (100) BINDINGDB
2XA	Ki: 200 nM (100) BINDINGDB
2XA	Ki: <50 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.6 Å
• R-Value Free: 0.257 
• R-Value Work: 0.181 
• Space Group: P 3₂

Unit Cell:

Length (Å)	Angle (°)
a = 96.770	α = 90.00
b = 96.770	β = 90.00
c = 124.751	γ = 120.00

Software Package:

Software Name	Purpose
SCALA	data scaling
REFMAC	refinement
iMOSFLM	data reduction
MOLREP	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2010-03-31 
• Released Date: 2011-03-30 
• Deposition Author(s): Kaan, H.Y.K., Weiss, J., Menger, D., Ulaganathan, V., Tkocz, K., Laggner, C., Popowycz, F., Joseph, B., Kozielski, F.

Revision History 

• Version 1.0: 2011-03-30
  Type: Initial release
• Version 1.1: 2011-05-19
  Type: Version format compliance
• Version 1.2: 2011-07-13
  Type: Version format compliance